Video

Dr Thorvardur Halfdanarson on if He Thinks There's a Future For Immunotherapy in NETs

It’s fair to say that the initial results of immunotherapy in neuroendocrine tumors (NETs) have been somewhat disappointing, explained Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic.

It’s fair to say that the initial results of immunotherapy in neuroendocrine tumors (NETs) have been somewhat disappointing, explained Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic.

Transcript

Is there a future for immunotherapy in neuroendocrine tumors?

I think there is a future for immunotherapy. The problem is that we don’t know who these patients are, who will respond. So, if we look at other cancers like lung cancer where we have a reliable biomarker, such as PD-L1, gastrointestinal malignancies where we have a reliable marker of a response, such as microsatellite instability. We don’t have that in neuroendocrine tumors. They are generally microsatellite stable tumors, and although they may and often express PD-L1, we don’t have good data to suggest that being a good marker. We know from small cell carcinoma of the lung that it probably doesn’t matter a whole lot what your PD-L1 expression is.

So, I think it’s fair to say that the initial results have been somewhat disappointing, but there are still signals and they’re suggesting to me that we need to pursue this as possible therapy. It’s just too hard to say where this will fit in. There are new trials coming down the pike for other malignancies using a combined approach with 2 immunotherapy agents with immunotherapy and cytotoxic therapy, and even immunotherapy with ablative therapies, such as the hepatic embolization or PRRT [peptide receptor radionuclide therapy] is something that I think would be very reasonable to explore.

So, immunotherapy is, I think, is still a target we should go after.

Related Videos
Drs Lillian L. Siu and Matthew G. Vander Heiden
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Kimberly Westrich, MA, chief strategy officer, NPC
Marla Black Morgan, MD, Phoebe Neurology Associates
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Richard Nowak, MD, MS, Yale School of Medicine
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo